Xtek Ltd - XTEK (ASX:XTE) Signs Exclusive Distribution Agreement with Rapid Biosecurity Screening Company KeyOptions Pty Ltd
Xtek Ltd (ASX:XTE)

XTEK (ASX:XTE) Signs Exclusive Distribution Agreement with Rapid Biosecurity Screening Company KeyOptions Pty Ltd

Highlights

What has happened?

XTEK (ASX:XTE) today announced that they have signed an exclusive distribution agreement with KeyOptions Pty Ltd for the sale and support of Virolens® in Australia, New Zealand and the Pacific independent states. Virolens® is a recently developed technology that can screen for SARS-CoV-2 in approximately 20 – 30 seconds and has been accepted by the UK Medical and Healthcare product Regulatory Agency (MHRA) with an application having been lodged by KeyOptions with the Therapeutic Goods Administration (TGA) in Australia as well.

What are the key highlights?

  • The Company reported that it has signed an exclusive distribution agreement with KeyOptions for the sale, distribution and support of Virolens®, a rapid COVID-19 diagnostic technology.
  • The signed agreement between XTEK and KeyOptions is set to initially last for two years, with year-to-year automatic renewal thereafter. Exclusivity of the contract is subject to minimum sales requirements in year 1.
  • Virolens® can screen for COVID-19 in approximately 20-30 seconds. The proof of concept demonstrated the Virolens® system had a 98.1% sensitivity and 99.7% specificity, based on the results of an internal in-vitro validation study of 184 samples.
  • The Virolens® product has been accepted by the UK MHRA for registration as an in vitro diagnostic (IVD) Medical Devices Directive 98/79/EC; and an application has been lodged with the TGA for registration as a Class 1 IVD medical device.

What does this announcement mean?

SmallCapInsider from Mawson Graham provides perspective on this recent announcement.
SmallCapInsider
Written by SmallCapInsider
Published Mar 30, 2021

What does this mean?

The signing of the exclusive distribution agreement by XTEK with KeyOptions for the Virolens® technology, is an interesting development as the Company expands its reach into the Biotech space. The signed agreement will initially kick-off for two years and could potentially be extended with automatic year-to-year renewal thereafter. Another significant factor in the signing is that Virolens® has been accepted by the UK Medical and Healthcare product Regulatory Agency (MHRA), which could hopefully pave the way for future approval by the Therapeutic Goods Administration (TGA), its Australian counterpart.

The Virolens® system detects COVID-19 quickly by using microscopic holographic imaging and artificial intelligence (AI) software technology. It uses a digital camera to capture holographic images to analyse saliva samples, with the data run through a neural network computer which is trained to identify the virus from other cells, delivering an end result in around 20-30 seconds. The proof of concept demonstrated the Virolens® system had a 98.1% sensitivity and 99.7% specificity, based on the results of an internal in-vitro validation study of 184 samples. No large clinical trial has yet been completed.

Revenues to XTEK from the sale of Virolens® are subject to the TGA approval and are dependent on potential end customers converting expressions of interest into firm orders. Once the TGA has approved the use of Virolens ®, it could hopefully play a significant role in opening the borders of Australia again to the world as society slowly learns to live with the ever-present COVID-19 virus.

file

The information within this section has been provided by Mawson Graham Pty Ltd and is for general information purposes only and is not intended to reflect any recommendations or financial advice. The information in this section has been prepared without taking into account your objectives, financial situation or needs. For this reason, you should consider the appropriateness of the advice or recommendation in light of your own personal circumstances, relevant risk factors, the nature and extent of your risk of loss, as well as the legal and accounting consequences before acting making an investment or trading decision regarding any Financial Product mentioned herein. While it is believed that all information sourced and contained within this section to be accurate at the time of publication, liability for any errors, omissions, accuracy or completeness of the information (except any statutory liability which cannot be excluded) is specifically excluded by Mawson Graham Pty Ltd, its associates, officers, directors, employees and agents. Past performance is not a reliable indicator of future performance. Important Disclosure: Mawson Graham Pty Ltd, its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage, investor relations fees, corporate fees, and other benefits or advantages, either directly or indirectly from client transactions arising from any information mentioned within this section and in documents published within this section.
Mawson Graham
Mawson Graham

Download Announcement

View this announcement as well as our full profile on the company.

How do I invest?

Considering investing in Xtek Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:XTE

    On your online investment platform search for the stock ticker code ASX:XTE to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up